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Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against
T-cell acute lymphoblastic leukemia: targeting the unfolded
protein response signaling
F Buontempo1, E Orsini1, LR Martins2, I Antunes2, A Lonetti1, F Chiarini3,4, G Tabellini5, C Evangelisti3,4, C Evangelisti1, F Melchionda6,
A Pession6, A Bertaina7, F Locatelli7, JA McCubrey8, A Cappellini9, JT Barata2 and AM Martelli1,3,4
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute lymphoblastic leukemia (T-ALL).
CK2 phosphorylates PTEN (phosphatase and tensin homolog) tumor suppressor, resulting in PTEN stabilization and functional
inactivation. Downregulation of PTEN activity has an impact on PI3K/Akt/mTOR signaling, which is of fundamental importance for
T-ALL cell survival. These observations lend compelling weight to the application of CK2 inhibitors in the therapy of T-ALL. Here,
we have analyzed the therapeutic potential of CX-4945—a novel, highly specific, orally available, ATP-competitive inhibitor of CK2a.
We show that CX-4945 treatment induced apoptosis in T-ALL cell lines and patient T lymphoblasts. CX-4945 downregulated
PI3K/Akt/mTOR signaling in leukemic cells. Notably, CX-4945 affected the unfolded protein response (UPR), as demonstrated by a
significant decrease in the levels of the main UPR regulator GRP78/BIP, and led to apoptosis via upregulation of the ER stress/UPR
cell death mediators IRE1a and CHOP. In vivo administration of CX-4945 to a subcutaneous xenotransplant model of human T-ALL
significantly delayed tumor growth. Our findings indicate that modulation of the ER stress/UPR signaling through CK2 inhibition
could be exploited for inducing apoptosis in T-ALL cells and that CX-4945 may be an efficient treatment for those T-ALLs displaying
upregulation of CK2a/PI3K/Akt/mTOR signaling.
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INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematologic tumor resulting from the malignant transformation
of T-cell progenitors. T-ALL accounts for 10–15% of pediatric and
25% of adult ALL cases.1,2 Although originally associated with high
relapse rates, the prognosis of T-ALL has gradually improved with
the introduction of intensified chemotherapy, with cure rates
reaching over 75% in children and about 50% in adults.3 However,
the outcome of T-ALL patients with primary resistant or relapsed
leukemia remains poor, highlighting the need to develop novel
targeted therapeutic strategies.4–12 Casein kinase 2 (CK2) is an
ubiquitously expressed and constitutively active serine/threonine
kinase that phosphorylates an impressive array of substrates13 and
is involved in disparate cellular processes. However, the most
prominent role of CK2 is the global promotion of cell growth and
prevention of apoptosis.14 There is compelling evidence that CK2
operates as a ‘cancer driver’ by creating a cellular environment
positive to neoplastic cells.15 Overexpression and hyperactivation
of CK2 have mostly been observed in solid tumors16 but also in
some blood malignancies,17 including multiple myeloma (MM),18
acute myeloid leukemia19 and T-ALL.20 CK2 is therefore
considered a promising target for innovative cancer treatment
and CK2 inhibitors display cytotoxic effects against cancer cells.21–23
CX-4945 is a potent CK2 inhibitor24 that has recently entered
phase I clinical trials in patients with advanced solid cancers
(NCT00891280) and in MM patients (NCT01199718). Regarding
T-ALL, the functions of CK2 are intimately linked with the inositol
lipid phosphatase PTEN (phosphatase and tensin homolog),
a negative regulator of the PI3K/Akt/mTOR pathway, which is
frequently upregulated in T-ALL patients.20 In primary T-ALL cells,
CK2-mediated phosphorylation of PTEN at its C-terminus resulted
in PTEN stabilization and functional inactivation, with ensuing
increase in PI3K/Akt/mTOR signaling.25 In the scenario of T-ALL,
another major signaling pathway, the endoplasmic reticulum (ER)
stress/unfolded protein response (UPR) pathway, is gaining
increasing recognition.26,27 Tumor cells are often exposed to
hypoxia, oxidative stress and metabolic dysregulation that cause
ER stress and activation of the UPR.28 UPR signaling is an
important mechanism required by cancer cells to maintain
malignancy and gaining therapy resistance. In fact, cancer cells
depend on ER integrity to maintain the correct structure of
oncokinases. For this reason, whereas UPR is involved in drug
resistance, cancer cells are ‘paradoxically’ more sensitive than
healthy cells to UPR changes, and pharmacologically sustained
induction or repression of UPR may have therapeutic effects
against cancer cells.29 In this context, it was recently documented
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that CK2 inhibition caused MM cell apoptosis through alterations
of the UPR signaling pathway,30 whereas in T-ALL, it was shown
that the downregulation of UPR drives apoptotic cell death.26,27
However, it remains to be determined whether a link between CK2
and regulation of UPR exists in T-ALL. In the present study, we
report the cytotoxic effects induced by the inhibition of CK2 with
CX-4945 on a panel of T-ALL cell lines and primary cells from T-ALL
patients. CK2 inhibition by CX-4945 potently downregulated UPR
signaling. We also observed that a combination of CX-4945 with
thapsigargin, an ER stress inducer, displayed significant synergistic
cytotoxic activity. Moreover, CX-4945 was efficacious in a
subcutaneous human T-ALL xenograft mouse model. Overall,
our findings establish a link between CK2 activity and UPR
signaling in T-ALL cells and could lead to the design of more




CX-4945 used in vivo studies was kindly provided by Cylene Pharmaceu-
ticals (San Diego, CA, USA). CX-4945 and temsirolimus for in vitro studies
were from Selleck Chemicals (Houston, TX, USA). Allophycocyanin-
conjugated antibody to CD45 was from Beckman Coulter (Miami,
FL, USA). Antibody to Ser129 p-Akt, geldanamycin, okadaic acid and
insulin-transferrin-sodium selenite were from Sigma-Aldrich (St Louis, MO,
USA). All of the other primary and secondary antibodies for western
blotting and flow cytometry analyses were from Cell Signaling Technology
(Danvers, MA, USA). Thapsigargin was from Santa Cruz Biotechnology
(Dallas, TX, USA).
Cell culture and primary T-ALL samples
T-ALL cell lines were grown in RPMI 1640, supplemented with either 10 or
20% heat-inactivated fetal bovine serum, depending on the cell line. MS-5
mouse stromal cells were grown in MEM Alpha medium supplemented
with 10% fetal bovine serum. Patient samples were obtained after
informed consent according to the Institutional guidelines and isolated
by Ficoll-Paque (Amersham Biosciences AB, Uppsala, Sweden). T-ALL
lymphoblasts were cultured in RPMI 1640 containing 20% fetal bovine
serum and insulin-transferrin-sodium selenite.
Cell viability analysis
MTT (3-[4,5-Dimethylthythiazol-2-yl]-2,5-Diphenyltetrazolium Bromide)
assays were performed as previously reported.31 For drug-combination
experiments, a combination index (CI) number was calculated using the
CalcuSyn software (BioSoft, Cambridge, UK) based on the Chou and Talalay
method.32 CI values between 0.1 and 0.9 define different grades of
synergism: values between 0.9 and 1.1 are additive, whereas values 41.1
are antagonistic.
Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI)
staining and cell cycle analysis
To determine the extent of apoptosis induction after drug treatment, flow
cytometric analysis of Annexin V-FITC/PI-stained samples was performed as
previously reported.31 Cell cycle analysis was carried out using a PI/RNaseA
staining according to standard procedures. All the flow cytometric analyses
were performed using an FC500 flow cytometer (Beckman Coulter).
Flow cytometric analysis of p-PTEN (Ser380), IRE1a and CHOP
levels
This was performed as reported elsewhere.31
Western blot analysis and immunoprecipitation
This was performed as previously detailed.33 Cells were lysed using the
M-PER Mammalian Protein Extraction Reagent, supplemented with the
Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific Inc,
Rockford, IL, USA). Akt immunoprecipitation was carried out as described
elsewhere.34
Jurkat cells coculture with MS-5 mouse stromal cells
Jurkat cells were seeded at 2.5 105/ml and, after an overnight incubation,
cell suspension was transferred on the top of MS-5 mouse stromal cells
(at B70% confluence) for 3 h before the addition of 5mM CX-4945. After 48 h,
Jurkat cells were harvested, washed and incubated with allophycocyanin-
conjugated anti-CD45 antibody or with an irrelevant isotypic control
antibody. After a 30-min incubation, cells were resuspended in binding
buffer containing Annexin V-FITC and analyzed using flow cytometry after
electronic gating on CD45þ leukemic cells.
Scanning electron microscopy (SEM) analysis of cocultured Jurkat
and MS-5 cells
After 48 h of incubation at 37 1C, cocultured cells were processed for
morphological studies using SEM, as reported elsewhere.35 Samples were
sputter-coated with 20-nm-thick palladium-gold film and examined under
a Philips SEM 515 operating at 15 kV.
Small interfering (siRNA) knockdown of CK2a
CEM-S cells were transfected with the Amaxa T cell Nucleofector kit (Lonza,
Basel, Switzerland) according to the manufacturer’s optimized protocol kit
for this cell line. CEM-R cells (2 106 cells) were transfected with 300 nM of
siRNA CK2a-specific siGENOME SMARTpool siRNAs or aspecific (scrambled)
siRNA siCONTROL riscfree no. 1 (Dharmacon, Lafayette, CO, USA). Cells
were diluted to between 2 and 3 105/ml and incubated for further 48 h.
In vivo subcutaneous human T-ALL mouse model
Mice were housed and bred in a specific pathogen-free animal facility,
treated in accordance with the European Union guidelines and approval by
the Institutional Ethical Committee of Instituto de Medicina Molecular.
Eight weeks old nonobese diabetic/severe combined immunodeficient
mice were subcutaneously injected in both flanks with 10 106 MOLT-
4.Luc.GFP cells, generated as described,36 and resuspended in 100ml of
phosphate-buffered saline. On day 5, mice were injected with luciferin to
assess tumor burden by whole-body bioluminescence imaging and were
equally distributed in two groups to receive CX-4945 dissolved in 25 mM
disodium hydrogen phosphate (Na2HPO4) or vehicle control. Tumor
growth was monitored weekly by bioluminescence and caliper
measurements, and mice were weighed frequently to determine
treatment-induced toxicity. For bioluminescence imaging, mice were
anaesthetized, intraperitoneally injected with 150 mg D-luciferin (Caliper
Life Sciences, Hopkinton, MA, USA) per kg body weight and scanned with
an IVIS Lumina bioimaging device (Caliper Life Sciences) after 15 min, as
described.36 Total flux (photons per second) was calculated using the
Living Image software (Caliper Life Sciences).
Statistical analysis
The data are presented as the mean values from three separate
experiments±s.d. In vivo differences in tumor development were
determined by two-way analysis of variance (ANOVA). Differences were
considered significant for Po0.05.
RESULTS
CX-4945 induces both cytotoxic and cytostatic effects on T-ALL
cell lines
The effects of CX-4945 on a panel of T-ALL cell lines were tested
by incubating the cells for 48 h with increasing concentrations of
the drug and then analyzing the rates of viability using MTT
assays. T-ALL cell lines displayed IC50s to CX-4945 ranging from
4.0 mM for CEM-R (drug-resistant) cells to 9.0 mM for DND-41 cells
(Figure 1a). To evaluate whether the effects of CX-4945 on cell
viability could be related to apoptosis, flow cytometric analysis
was performed. In response to treatment with 5 mM CX-4945, we
detected an increase in the percentage of early apoptotic (positive
for Annexin V) and/or late apoptotic (positive for both Annexin V
and PI) cells after either 24 or 48 h of treatment of T-ALL cell lines
(Figure 1b).
Apoptosis was further investigated by western blotting, which
documented a time-dependent cleavage of caspase-3 and poly
(ADP-ribose) polymerase in response to CX-4945 (Figure 1c).
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Figure 1. CX-4945 induces cytotoxic and cytostatic effects in T-ALL cell lines. (a) MTT assays of T-ALL cell lines treated with CX-4945 for 48 h.
Corresponding IC50 values are indicated for each cell line in the table. Data are representative of three independent experiments and s.d. was
o10%. (b) Flow cytometric analysis of Annexin V-FITC/PI-stained T-ALL cells treated with CX-4945 for different times. The percentages of early
apoptotic cells (Annexin V FITCþ /PI ; bottom right quadrant) and late apoptotic/necrotic cells (Annexin V FITCþ /PIþ ; top right quadrant)
are indicated. ctrl, untreated cells. (c) Western blot analysis documenting a time-dependent activation of caspase-3 and cleavage of poly
(ADP-ribose) polymerase by CX-4945 (5 mM). Fifty micrograms of protein were blotted to each lane. Antibody to b-actin served as a loading
control. Molecular weights are indicated at right. (d) Flow cytometric analysis of cell cycle distribution in T-ALL cell lines treated with CX-4945
(5mM) for 24 h. The histograms are representative of three separate experiments performed in duplicate. ctrl, control cells.
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The effects of CX-4945 on cell cycle progression were also
studied. Flow cytometric analysis of PI-stained T-ALL cells treated
with CX-4945 for 24 h revealed a block in the G2/M phase of the
cell cycle in MOLT-4, CEM-R and CEM-S (parental) cell lines.
In contrast, in DND-41 cells, we only detected an increase in sub-G1
cells, corresponding to apoptotic cells (Figure 1d). Taken together,
our findings demonstrated that CX-4945 had both cytostatic and
cytotoxic effects on T-ALL cell lines by promoting cell cycle arrest
at the G2/M phase of the cell cycle and by inducing apoptosis.
PI3K/PTEN/Akt/mTOR signaling pathway modulation by CX-4945
To study CK2 expression levels in T-ALL cell lines and to
demonstrate that CX-4945 effectively inhibited CK2 activity, we
incubated cells with 5 mM CX-4945 at different time points, and
then performed the analysis of protein expression using western
blot. CK2 protein levels were variable among T-ALL cell lines.
However, they did not change after CX-4945 treatment. PTEN is
one of the best known targets of CK2.25 Western blot analysis of
PTEN-positive T-ALL cell lines (HBP-ALL, ALL-SIL, DND-41) using an
antibody to a CK2-targeted amino-acidic residue (Ser380)37
demonstrated time-dependent PTEN dephosphorylation in
response to CX-4945, whereas the total levels of PTEN did not
change (Figure 2a). As expected, PTEN-deleted T-ALL cell lines
(Jurkat, CEM-S, PF-382) did not display any PTEN and p-PTEN
expression.
Next, we performed a concentration-dependent study of PTEN
dephosphorylation by CX-4945 in PTEN-expressing T-ALL cell lines.
Western blot analysis demonstrated that PTEN dephosphorylation
was already detectable at 2.5 mM CX-4945 after 24 h of treatment
with the inhibitor (Figure 2b). Furthermore, CX-4945 down-
regulated Akt phosphorylation at Ser129, which is targeted by
CK2,38 in both DND-41 and CEM-R cell lines (Figure 2c). Thus, our
data indicate that CK2 inhibition using CX-4945 induced time-
and/or dose-dependent Ser380 PTEN and Ser129 p-Akt dephospho-
rylation in T-ALL cell lines.
Given that T-ALL cells frequently display hyperactivation of
PI3K/Akt/mTOR signaling as a consequence of functional inhibi-
tion of PTEN mediated by CK2,25 the activation status of this
pathway was further evaluated. Western blot analysis documented
a time-dependent decrease in Thr308 p-Akt in T-ALL cell lines
exposed to the CX-4945, whereas total Akt levels were unaffected
by the inhibitor. Moreover, the mTOR complex 1 (mTORC1)
downstream substrate S6RP was efficiently dephosphorylated by
CX-4945 already after 1–3 h of treatment, whereas its total level of
expression did not change (Figure 2d).
Since we observed dephosphorylation of p-Akt at Thr308 in
both PTEN-expressing and PTEN-deleted cell lines, we sought an
Figure 2. Molecular effects of inhibition of CK2 after treatment with CX-4945 and modulation of the activation status of the PI3K/PTEN/Akt/
mTOR signaling pathway in T-ALL cell lines. (a) Cells were cultured for different times in the presence of 5 mM of CX-4945, and western blot
analysis was then performed. CK2 protein levels did not change after CX-4945 treatment. CX-4945 induced a time-dependent
dephosphorylation of PTEN (at Ser380). (b) Western blot analysis documenting the concentration-dependent effects of CX-4945 on Ser380
p-PTEN. (c) Western blot analysis documenting the concentration-dependent effects of CX-4945 on Ser129 p-Akt. In b and c treatment time
with the drug was 24 h. (d) CX-4945 (5 mM) induced a time-dependent dephosphorylation of Thr308 p-Akt and Ser235/236 p-S6RP. In a–d,
50micrograms of protein were blotted to each lane. Antibody to b-actin served as a loading control. Molecular weights are indicated at right.
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explanation for this phenomenon. It has been documented that
CK2-mediated phosphorylation of Akt at Ser129 increased Akt
association with the chaperone protein HSP-90 and protected Akt
from PP2A phosphatase activity on Thr308.39 Using CEM-R cells,
we immunoprecipitated Akt and we analyzed its association with
HSP-90 using western blot. Whereas the total levels of
immunoprecipitated Akt did not change in response to CX-4945
treatment, those of HSP-90 did indeed decrease (Supplementary
Figure S1A). Moreover, when CEM-R cells were treated with
geldanamycin, an inhibitor of HSP-90,40 we observed a reduction
in Thr308 p-Akt levels, whereas the levels of Ser473 p-Akt, Ser129
p-Akt, Akt, and HSP-90 did not change (Supplementary Figure
S1B). Furthermore, the PP2A inhibitor, okadaic acid, prevented
dephosphorylation of Thr308 p-Akt caused by CX-4945
(Supplementary Figure S1C). Overall, these findings indicated that
CX-4945 not only downregulated PTEN phosphorylation but also
disrupted the interactions between Akt and HSP-90 independently
of PTEN, thus rendering the Thr308 residue of Akt more
susceptible to the action of protein phosphatase PP2A.
CX-4945 affects viability of Jurkat cells even in the presence of MS-5
stromal cell support
As interactions between bone marrow stromal cells and leukemic
cells are thought to be responsible for decreased anti-leukemic
drug sensitivity,41 we investigated whether CX-4945 could bypass
the support of stromal cells and induce apoptotic cell death in a
coculture system. We used the murine stromal cell line MS-5,
which is known to provide long-term support for primitive
hematopoietic progenitors and to mimic the bone marrow
microenvironment.42 Coculture with stromal cells decreased but
did not abolish the sensitivity of Jurkat cells to treatment with
CX-4945, when compared with Jurkat cells growing as suspension
cultures (Supplementary Figure S2A).
The effects of CX-4945 on Jurkat cells cocultured with MS-5
stromal cells were studied also by SEM. Untreated Jurkat cells
displayed typical microvillous expansions evenly distributed over
the intact cell membrane (Supplementary Figure S2B, left). Jurkat
cells treated with CX-4945 displayed cell shrinkage, loss of surface
microvilli and disappearance of cell-to-cell contacts. Many
detached apoptotic-like bodies were observed (Supplementary
Figure S2B, center). Moreover, leukemic cells exhibited plasma
membrane alterations, including perforation and blebbing
(Supplementary Figure S2B, right), suggestive of apoptosis.
CK2 inactivation by CX-4945 or siRNA affects ER stress/UPR
signaling
It has been documented, in different tumor models, that
CK2 inhibition induces apoptosis through inhibition of UPR
mechanisms.43,44 These observations extend to T-ALL, where down-
regulation of UPR was shown to drive apoptotic cell death.26,27,45
To better understand the molecular mechanisms involved in
CX-4945-mediated T-ALL cell death, we studied the effect of CK2
inhibition on ER stress/UPR signaling. We found a decrease in the
expression of GRP78/BIP (a marker of UPR activation26) starting
after 3–6 h of drug treatment, implying that CK2 inactivation led to
UPR inhibition (Figure 3). In contrast, the expression of IRE1a,
p-EIF2a and CHOP increased after exposure to CX-4945, indicating
concomitant induction of significant stress in the ER lumen
Figure 3. CX-4945 modulates ER stress/UPR signaling in T-ALL cell lines. Western blot analysis documenting the time-dependent modulation
of ER stress/UPR signaling markers induced by CX-4945 (5 mM) in T-ALL cell lines. Fifty micrograms of protein were blotted to each lane.
Antibody to b-actin served as a loading control. Molecular weights are indicated at right.
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(Figure 3). Indeed, IRE1a, p-EIF2a and CHOP are well-established
markers of ER stress/UPR-mediated apoptosis.46 Therefore, our
findings suggested that a potential mechanism by which CX-4945
induced T-ALL cell death involved ER stress induction and the
inability of leukemic cells to adequately respond to ER stress by
upregulating the UPR.
We next employed an siRNA strategy to downregulate CK2a in
CEM-S cells (Figure 4a) and analyze the effects on cell viability and
ER stress/UPR signaling response. MTT assays demonstrated a
significant reduction in cell viability of CEM-S cells treated for 48 h
with siRNA specific to CK2a in comparison to control siRNA
(Figure 4b). Western blot analysis documented a decrease in
GRP78/BIP and an increase in IRE1a and p-EIF2a in cells with
downregulated CK2a expression (Figure 4c). The results obtained
with siRNA downregulation of CK2a in CEM-S cells were similar to
those obtained through CK2 chemical inhibition by CX-4945
(Figure 4d).
CX-4945 synergizes with temsirolimus, an allosteric mTORC1
inhibitor
The relationship between protein translation and UPR activation
has been recently highlighted. Hyperactivation of eukaryotic
initiation factor 4E-binding protein 1 (4E-BP1), resulting from the
inhibition of mTORC1 signaling, was shown to prevent GRP78/BIP
induction and consequently led to the failure of UPR.47 CX-4945
was able to inhibit UPR while causing p-4E-BP1 dephosphorylation
in T-ALL cell lines (data not shown). Thus, we investigated whether
CX-4945 synergized with the mTORC1 inhibitor, temsirolimus,
in T-ALL cell lines.
MOLT-4 and Jurkat cells were incubated for 48 h with either
drug alone or with their combination at a fixed ratio. We found a
strong synergism (CI p0.3) in both MOLT-4 and Jurkat cells at a
CX-4945 concentration (1mM) clearly below the respective IC50 in
these cells (Supplementary Figure S3A). The effects of the drug
combination on apoptosis were determined with Annexin V-FITC/
PI staining. After 48 h, the combined treatment was more effective
in inducing apoptosis than single treatments (Supplementary
Figure S3B). To study the effects of the drug combination on ER
stress/UPR signaling, western blot analysis was performed after
24 h of treatment. CX-4945 and temsirolimus synergized in
decreasing GRP78/BIP and p-4E-BP1 levels, and in increasing
IRE1a and CHOP expression (Supplementary Figure S3C). These
findings confirmed that the drug combination induced apoptotic
cell death through ER stress/UPR signaling modulation.
CX-4945 synergizes with the ER stress inducer thapsigargin
The therapeutic potential of targeting UPR signaling in cancer
mainly involves two approaches: inhibition of UPR to hit tumors
with a highly stressed ER that are strongly dependent on an
activated UPR for their survival,30 or induction of accumulation of
misfolded proteins in ER to overload restoration capacity of
tumors with a previously compromised UPR.48 As we
demonstrated that, in T-ALL cells, CX-4945 treatment inhibited
UPR, we next studied the existence of a potential synergism
between CX-4945 and thapsigargin, a sarcoplasmic Ca2þATPase
inhibitor, which is a powerful inducer of both ER stress and UPR.48
MOLT-4 and PF-382 cells were incubated for 48 h either with each
drug alone or with a combination of the two drugs at a fixed ratio.
Using MTT assays, we observed a moderate (MOLT-4 cells) or
strong (PF-382 cells) synergism at CX-4945 concentrations (2.5 and
1 mM, respectively) clearly below their respective IC50 in these cells
(Figure 5a). Flow cytometric analysis of Annexin V-FITC/PI-stained
cells confirmed that the drug combination was more effective
than each single agent in inducing apoptosis (Figure 5b). More-
over, CX-4945 and thapsigargin synergized in enhancing IRE1a
and CHOP expression, thus suggesting that thapsigargin increased
ER stress induced by CX-4945. As expected, thapsigargin activated
UPR and this was documented by the strong enhancement of
GRP78/BIP expression, also in combination with CX-4945. p-4E-BP1
behaved as GRP78/BIP (Figure 5c). Overall, these findings
suggested that the blockage of UPR induction observed in T-ALL
Figure 4. CK2a downregulation by siRNA affects CEM-S cell viability and modulates ER stress/UPR signaling. (a) Western blot analysis
confirmed that CK2a was efficiently down-modulated upon nucleofection of CEM-S cells with specific siRNA, whereas scrambled (control)
siRNA had no effect. (b) MTT analysis of CEM-S cells nucleofected with 300 nM of siRNA to CK2a documented a significant reduction in cell
viability when compared with scrambled siRNA-transfected cells (Po0.05). Results are the mean of three different experiments±s.d.
(c) Western blot analysis demonstrated that CK2a downregulation affected the expression levels of ER stress/UPR signaling markers as
chemical treatment with 5 mM CX-4945 for different time periods (d).
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Figure 5. CX-4945 synergizes with thapsigargin in T-ALL cells. (a) MTT assays of MOLT-4 and PF-382 cell lines treated for 48 h with CX-4945
alone or in combination with thapsigargin (TH) at a fixed ratio. The combined treatments resulted in a moderate synergism (CI: 0.3–0.7) in
MOLT-4 cells and in a strong synergism (CI: 0.1–0.3) in PF-382 cells. Data are representative of three independent experiments and s.d. was
o10%. (b) Flow cytometric analysis of Annexin V-FITC/PI-stained MOLT-4 and PF-382 cells treated for 24 h with CX-4945 and thapsigargin
either alone or in combination documented that the combined treatment was more effective in inducing apoptosis than single treatments.
Ctrl, untreated cells. (c) Western blot analysis of cells treated for 24 h with CX-4945 and thapsigargin, either alone or in combination, showed
that drugs synergized in enhancing IRE1a and CHOP expression, suggesting that thapsigargin increased ER stress induced by CX-4945
treatment. In contrast to CX-4945, thapsigargin activated UPR and this was documented by the strong enhancement of GRP78/BIP expression,
also in combination with CX-4945. p-4E-BP1 behaved as GRP78/BIP. Fifty micrograms of protein was blotted to each lane. Antibody to b-actin
served as a loading control. Molecular weights are indicated at right. In a–c, TH: thapsigargin.
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cells treated with CX-4945 was not able to switch off the ER stress
induced by thapsigargin, thus leading to leukemic cell apoptosis.
CX-4945 is effective in primary T-ALL blasts
To better assess the effectiveness of CX-4945 as a potential
therapeutic agent in T-ALL, we studied four pediatric T-ALL patient
samples isolated from the bone marrow. Cells were treated with
increasing concentrations of the drug for 24 h, and the rates of
survival were analyzed by MTT assays. The CX-4945 IC50 for patient
samples ranged from 0.45 to 3.0 mM (Figure 6a). CX-4945 induced
apoptosis in T-ALL lymphoblasts, as documented using flow
cytometric analysis of Annexin V-FITC/PI-stained samples
(Figure 6b). Consistent with findings obtained in T-ALL cell lines,
CX-4945 downregulated Ser380 p-PTEN and upregulated both
IRE1a and CHOP, as documented using flow cytometric analysis
(Figure 6c). Western blot analysis demonstrated inhibition of UPR
signaling (reduction of the GRP78/BIP level) and induction of ER
stress (increase in the levels of IRE1a) in patient samples
(Figure 6d).
CX-4945 delays T-ALL tumor growth in vivo
The significant in vitro antitumor activity of CX-4945 on T-ALL cells
led us to further explore its therapeutic potential by investigating
the anti-leukemic efficacy of CX-4945 in an animal model of
human T-ALL. Nonobese diabetic/severe combined immunodefi-
cient mice were injected subcutaneously with MOLT-4.Luc.GFP
cells. On day 5 after cell transfer, mice were equally distributed
according to tumor burden in two groups to receive CX-4945
Figure 6. CX-4945 is cytotoxic to primary lymphoblasts from T-ALL patients (Pt) and affects ER stress/UPR signaling in T-ALL patients. (a) MTT
assays of T-ALL blasts from four pediatric patients treated with CX-4945 for 24 h and their corresponding IC50 values. Data are representative
of three independent experiments and s.d. was o10%. (b) Flow cytometric analysis of Annexin V-FITC/PI-stained T lymphoblasts, treated with
CX-4945, documented a significant and a dose-dependent increase in apoptotic cells. A representative patient is shown. Ctrl, untreated cells.
(c) Flow cytometric analysis demonstrated a significant decrease in the expression levels of Ser380 p-PTEN, and an increase in the levels of
both IRE1a and CHOP proteins after 10 mM CX-4945 treatment for 24 h. Data are the mean from three patients. Asterisks indicate statistically
significant differences with respect to untreated cells, considered as 100% (***Po0.0005). Ctrl, untreated cells. (d) Western blot analysis of
proteins extracted from T-ALL lymphoblasts confirmed an increase in the quantity of IRE1a and a decrease in GRP78/BIP expression levels.
A representative patient is shown. Fifty micrograms of protein were blotted to each lane. Antibody to b-actin served as a loading control.
Molecular weights are indicated at right.
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(75 mg/kg, orally, twice a day) or vehicle control. We observed a
significant delay in tumor growth in the CX-4945-treated group at
3 and 4 weeks (Figures 7a and b, P¼ 0.015; two-way ANOVA)
without significant toxicities (not shown). Taken together, our data
indicate that inhibition of CK2 activity using CX-4945 may be an
useful therapeutic strategy for T-ALL.
DISCUSSION
The clinical-stage CK2a inhibitor CX-4945 has been tested in
hematological malignancies that include chronic myeloid leuke-
mia49 and B-cell chronic lymphocytic leukemia.50,51 The findings
that emerged from these studies have provided preclinical
evidence that CK2a could be a valuable therapeutic target in
blood cancers and supported the possible initiation of clinical
trials using CK2a antagonists in the context of hematological
malignancies. These may potentially include also CIGB-300, the
only other currently available clinical-grade CK2 inhibitor, which
has shown significant antitumor effects in murine cancer models
and was safe and well tolerated in phase I clinical trials in cervical
cancer that demonstrated tumor reduction.52
In this study, we have evaluated the therapeutic potential of
CX-4945 in preclinical settings of T-ALL. There is a strong rationale
for targeting CK2a in T-ALL, as this kinase phosphorylates and
inactivates the inositol lipid phosphatase PTEN,20 which results in
downregulation of PTEN function and in enhanced activity of
the PI3K/Akt/mTOR signaling network, that has a key role in
proliferation, survival and drug resistance of T-ALL cells.53
We showed that CX-4945 reduced cell viability in a
concentration-dependent manner in all the tested T-ALL cell
lines and primary patient samples and was effective in both
PTEN-expressing and PTEN-deleted T-ALL cell lines, suggesting
that CK2 inhibition targets both PTEN-dependent and
PTEN-independent T-ALL cell viability.
The cytotoxic effects of CX-4945 were accompanied by
evidence of CK2a activity inhibition, as documented by the
concentration- and/or time-dependent dephosphorylation of two
main direct targets of CK2a, Ser380 p-PTEN and Ser129 p-Akt.
The outcome of Akt phosphorylation at Ser129 by CK2a is still
debated. However, it has been proposed that this phosphorylative
event enhances Akt interactions with the chaperone protein
HSP-90,39 which protects Akt from protein phosphatase PP2A
acting on the Thr308 residue of Akt.54 In agreement with this
theory, we observed that CX-4945 dephosphorylated Thr308 p-Akt
in both PTEN-expressing and PTEN-deleted T-ALL cell lines.
Accordingly and in agreement with previous findings,39 the
amount of Akt associated with HSP-90 was markedly decreased by
CX-4945. Moreover, geldanamycin, a drug that disrupts the
interactions between Akt and HSP-90, reduced the levels of
Thr308 p-Akt (but not those of Ser473 p-Akt), thus mimicking the
effects of CX-4945, while okadaic acid, a PP2A inhibitor,54 opposed
the effects of CX-4945 on Thr308 p-Akt. It is worth remembering
here that the Ser473 residue of Akt is dephosphorylated by the
PHLPP protein phosphatase.55
The CX-4945 cytotoxic effects correlated with a significant
induction of apoptosis and cleavage of caspase-3 and poly (ADP-
ribose) polymerase. Moreover, treatment with CX-4945 induced
cell cycle arrest in the G2/M phase of the cell cycle in most of T-ALL
cell lines. These findings suggest that CK2 inhibition resulted in
deregulation of mechanisms involved in cell cycle progression and
mitosis regulation and are in line with the well-documented roles
played by CK2a during the G2/M phase of the cell cycle.
56
As survival signals generated by cytokines secreted by cells of
the bone marrow microenvironment have an important role in the
emergence of drug resistance, we evaluated whether CX-4945
could diminish these survival signals. Interestingly, CX-4945
retained most of its pro-apoptotic activity even when Jurkat cells
were cocultured with MS-5 murine bone marrow stromal cells.
Of note, we extended our observations on the therapeutic
potential of CX-4945 in T-ALL by showing that in vivo adminis-
tration of CX-4945 to a subcutaneous xenotransplant model of
human T-ALL significantly delayed tumor growth.
It is emerging that downregulation of UPR signaling pathway
drives apoptotic cell death in preclinical models of T-ALL.26,27
Moreover, Manni et al.30 recently reported that CK2 inhibition
caused a strong apoptotic response through alterations of the
UPR pathway in MM cells. CX-4945 was able to inhibit UPR
signaling in T-ALL cell lines and primary samples, as evidenced by
downregulation of GRP78/BIP, a marker of UPR activation.
However, CX-4945 also induced ER stress as demonstrated by
upregulation of IRE1a, p-EIF2a and CHOP expression levels. Thus,
we hypothesize that a potential mechanism by which CX-4945-
induced cell death in T-ALL cells involved the induction of ER
stress and the concomitant inability of leukemic cells to
adequately cope with the ER stress by properly activating UPR
signaling.45 Modulation of ER stress/UPR signaling markers,
through CK2 inhibition, was also confirmed by experiments in
which CK2a expression was down-modulated by siRNA. It should
be emphasized that changes in ER stress/UPR signaling were
detected in both PTEN-expressing and PTEN-deleted cell lines.
We have demonstrated that CK2 treatment downregulated
Thr308 p-Akt; however, it did not affect Ser473 p-Akt levels
(data not shown). Nevertheless, it has been established that
decreased Akt phosphorylation at Thr308 is sufficient to inhibit
mTORC1 activity.57 Consistently with mTORC1 inhibition, CX-4945
Figure 7. CX-4945 delays T-ALL tumor growth in vivo. Nonobese
diabetic/severe combined immunodeficient mice were injected
subcutaneously with 10 106 MOLT-4.Luc.GFP cells in each flank.
Five days after cell transfer, mice were equally distributed according
to tumor burden in 2 groups (n¼ 3 per group): Control (vehicle
control) and CX-4945 (CX-4945, 75mg/Kg, orally, twice a day). Tumor
burden was assessed at 3 weeks (a) or the indicated time points
(b) after cell transplantation (P¼ 0.015; two-way ANOVA).
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decreased the Ser235/236 p-S6RP levels. Therefore, down-
regulated mTORC1 activity could be the driving force for
inhibition of the UPR signaling in response to CX-4945 in T-ALL
cells,47,58 as we have demonstrated by the use of temsirolimus.
It remains to be established how CX-4945 induces ER stress in T-ALL,
as ER stress can be generated by the accumulation of unfolded
proteins, by depletion of amino acids or by oxidative stress.59
However, it should be underlined that T-ALL, unlike certain
secretory tumor types (MM, pancreatic adenocarcinoma), does not
rely on a high basal UPR activity,48 and in fact CX-4945 treatment
further depressed UPR signaling. In this scenario, treatment with
an ER stress inducer, thapsigargin, together with CX-4945, resulted
in synergistic killing of leukemic cells through modulation of the
ER stress/UPR signaling pathway, as reported in other tumors.60
Although at present existing ER stress inducers could not be used
in vivo because of their side effects, a combined treatment
consisting of CX-4945 and novel nontoxic ER stress inducers could
be considered as a therapeutic opportunity for future treatment
of T-ALL.
In conclusion, our results indicate, for the first time, that
modulation of the ER stress/UPR signaling through CK2 inhibition
could be exploited for inducing T-ALL cell death and that CX-4945
may be an efficient treatment for T-ALLs that have aberrant
upregulation of the CK2/PI3K/Akt/mTOR signaling pathway,
independently from PTEN expression.
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